The company, which was incorporated in April 2015 and is jointly owned by Oxurion NV and VIB, is focused on enhancing T cell migration, infiltration, and activity into resistant tumor sites. Their clinical development activities are centered on orphan pediatric oncology treatment with a focus on preclinical research and drug development programs. Oncurious NV is also working on therapies that eliminate CCR8-expressing immune-suppressive regulatory T cells, with the aim of boosting the anti-tumor immune response. They are investigating different therapeutic concepts around T cell exclusion from the tumor, enabling patients to receive new approaches for immuno-oncology drugs targeting a broad spectrum of cancers.